ImmunityBio Shares Surge on Promising Lung Cancer Trial Data
Published on 09/15/2025 at 08:27 | Redaktion boerse-global.deImmunityBio’s stock experienced a significant boost, climbing more than 8%, following the presentation of compelling new data from its Phase 2 clinical trial, QUILT-3.055. The data, unveiled at the World Conference on Lung Cancer, demonstrated that the company’s drug candidate, ANKTIVA, provided substantial survival benefits for patients with advanced non-small cell lung cancer who had ceased responding to conventional immunotherapy treatments.
This development introduces a potential turning point for the biotech firm, which has seen its share price decline more than 60% from its annual peak. The positive results could signal a reversal of fortune, pulling the equity out of its downward trend.
The investor excitement stems from ANKTIVA’s unique mechanism of action. The therapy is the first... Read more...
Disclaimer regarding our articles: No investment advice, no buy or sell recommendation. Information on prices, companies, and markets is provided without guarantee; changes are possible at any time. Stock market transactions can lead to substantial losses. Our articles are created and reviewed in whole or in part automatically with the support of AI.
